10 / 11
Page 72
allied
academies
Journal of Dermatology Research and Skin Care | Volume 2
May 14-15, 2018 | Montreal, Canada
Spring Dermatology &
Skin Care Expo Conference
Introduction:
In October 2016 I started, as one of the first in
Europe, my experience with a new procedure that represents
the only FDA-cleared minimally invasive treatment clinically
proven to improve the cellulite blemishes for nearly four
years in only one session.
Materials & Methods:
We report our experience after 15
months in 50 patients (48F; 2M) with cellulite treated in a
single session. Follow-up were scheduled after seven days
(T7), 14 days (T14), 30 days (T30), 90 days (T90) and 180 days
(T150) for all the 50 patients; 13 patients (1M) had a medical
check at 12 months and three patients (1M) at 15 months.
Outcome measures included subject photographs, Cellulite
Severity Scale (CSS) and Global Aesthetic Improvement Scale
(GAIS) assessment. Patient satisfaction and pain rating were
also recorded. The treatment takes 45-60 minutes. Cellulite
dimples are marked and the device is applied to stretch and
stabilize tissue in a vacuum chamber, while local anesthesia is
delivered. Then, a precise minimally-invasive subcutaneous
release of the connective bands (TS-GS: stabilized-guided
subcision) is performed with a micro-blade, without cuts
or incisions. We have safely treated six to 45 sites in one
session. After treatment, a light compression is applied and
patients are able to return promptly to their daily life.
Results:
The procedure treated successfully the primary
structural cause of cellulite blemishes in all the 50 patients.
Patient satisfaction was 87% at T90 in 50 patients (48F; 2M),
95% at T180 in 50 patients, 97% at 12 months in 13 patients
(1M) and 100% at 15 months in 3 patients (1M). Transient
treatment-related adverse events were mild in severity and
the most common side effects reported were soreness and
bruising. Among 50 patients, 95% had bruising at T7, 23% at
T14 and no patient had bruising at T30. Soreness is reported
in 100% of patients at T7, 19% at T14, 4% at T30 and 0% at
T90. Global Aesthetic Improvement Scale (GAIS) and Visual
Analog Scale (VAS) are also reported.
Conclusions:
This revolutionary FDA-cleared procedure for
the cellulite puckering combines a proven approach with an
innovative technology to treat the primary structural cause
of cellulite blemishes in posterior thighs and buttocks. This
study confirms his safety, and efficacy with vacuum-assisted
precise tissue release for the treatment of cellulite, which is
also strengthened by patient’s satisfaction.
e:
dellavanzato@hotmail.itA revolutionary mini-invasive treatment for cellulite blemishes: 15 months of initial experience
Roberto Dell’Avanzato
Teoxane Italia Training Center, Brazil